Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01723202
Title Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Comprehensive Cancer Network, Manisha Shah, Ohio State University Comprehensive Cancer Center

thyroid gland papillary carcinoma

thyroid gland follicular carcinoma


Dabrafenib + Trametinib


Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California, San Diego San Diego California 92093-0698 United States Details
University of Chicago Medical Center Chicago Illinois 60637 United States Details
Massachusetts General Hospital, Harvard Medical School Boston Massachusetts 02114 United States Details
Ohio State University Medical Center Columbus Ohio 43210 United States Details
The University of Texas-MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from for the field